13 February 2007 Pharmacokinetic assessment of a polymersome-based molecular beacon by in vivo fluorescence monitoring
Author Affiliations +
Abstract
Indocyanine Green (ICG) is currently the only FDA-approved contrast agent suitable for imaging tumor vascularity and performing permeability measurements. However, it is non-specific; clearance (wash-out) by the liver is very rapid, and tumor to normal tissue contrast is not optimal for medical imaging applications. Therefore, new ICG derivatives are being developed with improved affinity tumor cell affinity, and prolonged circulation times.1 Furthermore, several new contrast agents (molecular beacons) with specific tumor targeting have been reported. Tumor cells over-express certain receptors which results in an increased uptake of ligands specific to those receptors. Chemical conjugation of molecular beacons to such ligands allows for accumulation of the agents specifically at tumor cites. For example, Weissleder et al.2 have developed protease-activated molecular beacons that achieved a 12-fold tumor to normal tissue contrast. New molecular beacons might have direct impact on therapy monitoring: with higher sensitivity and specificity, one can noninvasively monitor and therapeutically intervene tumors in their early stages, which should lead to better survival rates.
© (2007) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Ulas Sunar, P. Peter Ghoroghchian, Xavier Intes, Michael J. Therien, Daniel A. Hammer, Arjun G. Yodh, "Pharmacokinetic assessment of a polymersome-based molecular beacon by in vivo fluorescence monitoring", Proc. SPIE 6434, Optical Tomography and Spectroscopy of Tissue VII, 64342I (13 February 2007); doi: 10.1117/12.700802; https://doi.org/10.1117/12.700802
PROCEEDINGS
5 PAGES


SHARE
Back to Top